Taysha Gene Therapies (TSHA) FCF Margin (2023 - 2025)
Taysha Gene Therapies (TSHA) reported FCF Margin of 2263.61% for Q4 2025, down 135827.0% on a YoY basis from N/an in Q4 2024, and down 118.55% sequentially from 1035.75% in Q2 2025.
Taysha Gene Therapies (TSHA) FCF Margin (2023 - 2025) Analysis & Trends
Taysha Gene Therapies (TSHA) has 3 years of FCF Margin data on file, last reported at 2263.61% in Q4 2025.
- For the quarter ending Q4 2025, FCF Margin fell 135827.0% year-over-year to 2263.61%; the trailing twelve-month figure through Mar 2026 stood at 3523.67% (down 236498.0% YoY), and the FY2025 full-year result was 1705.96%, down 72674.0% from the prior year.
- FCF Margin eased to 2263.61% in Q4 2025, from 1035.75% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 305.94% in Q3 2023 to a low of 2263.61% in Q4 2025.
- A 3-year average of 1005.02% and a median of 905.34% in 2024 frame the typical range for FCF Margin.
- Peak annual rise in FCF Margin reached 92549 bps in 2025, while the deepest fall reached 135827 bps in 2025.
- Tracing TSHA's FCF Margin over 3 years: stood at 542.81% in 2023, then slumped by 67 bps to 905.34% in 2024, then plunged by 150 bps to 2263.61% in 2025.
- Business Quant data shows TSHA's FCF Margin at 2263.61% in Q4 2025, 1035.75% in Q2 2025, and 957.56% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Taysha Gene Therapies | 2.14 Bn | 2.14 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2,263.61% |
| Jun 30, 2025 | -1,035.75% |
| Mar 31, 2025 | -957.56% |
| Dec 31, 2024 | -905.34% |
| Sep 30, 2024 | -1,205.03% |
| Jun 30, 2024 | -1,961.24% |
| Mar 31, 2024 | -584.52% |
| Dec 31, 2023 | -542.81% |
| Sep 30, 2023 | -305.94% |
| Jun 30, 2023 | -781.59% |
| Mar 31, 2023 | -511.79% |